LIBTAYO 350 mg concentrate for solution for infusion., HST-1011 5mg, HST-1011 40mg, HST-1011 150mg, HST-1011 10mg clinical trials

An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination with an Anti-PD1 Antibody in Patients with Advanced Solid Tumors

This study is testing a new medicine called HST-1011, by itself and with another medicine called Libtayo, for people with advanced cancers. Researchers want to see if these treatments are safe, how they work in the body, and if they help shrink tumors.